20/20 Biolabs, Inc. (AIDX): Financials
Fiscal year ended December 31, 2025
Income statement, cash flow and balance sheet figures for 20/20 Biolabs, Inc. (AIDX), read directly from the XBRL data the company files with the SEC. Over the most recent fiscal year the company reported $2.0M of revenue, up 16.7% year over year. Net loss was $3.7M, or $-0.76 per diluted share. Gross margin stood at 29.6%.
Against the current share price, AIDX trades at 3.5 times trailing revenue.
2 fiscal years of history are available, back to 2024.
Frequently asked questions
How much revenue does AIDX make?
20/20 Biolabs, Inc. reported $2.0M of revenue over the most recent fiscal year, for the period ended December 31, 2025. That is up 16.7% from the same period a year earlier.
Is AIDX profitable?
20/20 Biolabs, Inc. was unprofitable over the most recent fiscal year, with a net loss of $3.7M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.